# US 2019/0083601 A1 · Recombinant zika vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0083601 A1
- Document ID: US20190083601A1
- Status: Published application
- Kind: A1
- Application number: 16/063,239
- Filed: 2016-12-23
- Published: 2019-03-21
- Earliest claimed: 2015-12-23
- Assignees: Themis Bioscience GmbH
- Applicants: Themis Bioscience GmbH
- Inventors: Erich Tauber; Sabrina Schrauf; Matthias Müllner; Katrin Ramsauer; Angelika Irmler; Patrick Csar
- Web page: https://patentgrep.com/patent/US20190083601A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/165: Mumps or measles virus
- A61P 31/14: for RNA viruses
- B01D 15/361: {Ion-exchange}
- B01D 15/3804: {Affinity chromatography}
- B01J 20/282: Porous sorbents (ion exchange B01J39/00 - B01J41/00)
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 7/02: Recovery or purification
- C12N 15/86: Viral vectors
- C12N 2760/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/00051: Methods of production or purification of viral material
- C12N 2760/18051: Methods of production or purification of viral material
- C12N 2760/18434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18443: viral genome or elements thereof as genetic vector
- C12N 2770/24121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24151: Methods of production or purification of viral material
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2840/105: enhancing translation
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to the provision of immunogenic or vaccine compositions comprising at least one recombinant Zika virus antigen, wherein the at least one recombinant Zika virus antigen is encoded by at least one nucleic acid sequence encoding at least one E-protein of a Zika virus or a functional fragment thereof. Further provided are nucleic acid molecules and a recombinant chimeric virus encoding and/or comprising selected antigens from a Zika virus, which are suitable as vaccine compositions. Preferably, the sequences encoding at least one Zika virus antigens suitable for eliciting an immune response are operably linked to a non-flavivirus derived vector backbone. Further provided are methods for purifying the recombinant chimeric virus particles or the immunogenic composition. Finally, there is provided an immunogenic/vaccine composition for use in a method of preventing or treating a Zika virus disease.

## Claims

### Claim at position 1

-4. (canceled)

### Claim 5

A nucleic acid molecule comprising (i) first nucleic acid sequence encoding at least one E-protein of a Zika virus or a functional fragment of an E-protein of a Zika virus, and (ii) a second nucleic acid sequence encoding at least one E-protein signal sequence for a Zika virus E-protein or a functional fragment of an E-protein of a Zika virus, and optionally comprising (iii) a third nucleic acid sequence encoding at least one pre-membrane protein of a Zika virus or a functional fragment of a pre-membrane protein of a Zika virus, and optionally comprising (iv) a fourth nucleic acid sequence encoding at least one pre-membrane protein signal sequence for a Zika virus pre-membrane protein or a functional fragment of a pre-membrane protein signal sequence of a Zika virus, wherein the first and optionally the second and/or the third and/or the fourth nucleic acid sequence is/are independently derived from any one of SEQ ID NOs: 1 to 13 and 67 to 87, and wherein the nucleic acid molecule does not comprise a nucleic acid sequence encoding a C-protein of a flavivirus, and
(a) wherein the nucleic acid molecule additionally comprises a mutation within the first nucleic acid sequence at the position encoding amino acid position L107 of the E-protein of a Zika virus or the functional fragment of an E-protein of a Zika virus in comparison to the sequence of any one of SEQ ID NOs: 27 to 39, 40 to 52, 109 to 129 and 130 to 150, and optionally wherein the first nucleic acid sequence comprises a sequence encoding the stem anchor region of the E-protein of a Zika virus encoded by any one of SEQ ID NOs: 1 to 13 and 67 to 87, or wherein the E-protein of a Zika virus comprises a heterologous stem-anchor region selected from any one of SEQ ID NOs: 185 to 191, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence homology thereto, or
(b) wherein the nucleic acid molecule does not comprise a nucleic acid sequence encoding a stem anchor region of the E-protein of a Zika virus or a heterologous stem-anchor region for an E-protein of a Zika virus, or
(c) wherein the nucleic acid molecule does not comprise a further nucleic acid sequence encoding a non-structural protein of a flavivirus.

### Claim 6 (depends on 5)

The nucleic acid molecule according to claim 5, wherein the first or the second and/or the third and/or the fourth nucleic acid sequence is/are selected from the group consisting of SEQ ID NOs: 53 to 56 or 63 and 64 or a sequence having at least 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, wherein the nucleic add molecule encodes a functional Zika virus antigen.

### Claim at position 4

-15. (canceled)

### Claim 16 (depends on 5)

An amino acid molecule encoded by the nucleic acid molecule according to claim 5.

### Claim 17

An infectious replicative virus particle comprising (i) a nucleic acid molecule encoding an E-protein or a soluble E-protein of a Zika virus operably linked to (ii) a nucleic acid molecule encoding a measles virus scaffold vector backbone.

### Claim 18 (depends on 17)

The infectious replicative virus particle according to claim 17, wherein:
(a) the nucleic acid molecule encoding an E-protein or a soluble E protein does not comprise a sequence encoding a stem-anchor region of an E-protein of a Zika virus, or a heterologous stem-anchor region for an E-protein of a Zika virus; or
(b) the nucleic acid molecule encoding an E-protein or a soluble E-protein encodes at least one E-protein of a Zika virus or a functional fragment thereof having a mutation at amino acid position 107 in comparison to the sequence of any one of SEQ ID NOs:40 to 52 and 130 to 150, and optionally comprises at least one sequence encoding a stem anchor region of an E-protein of a Zika virus, or a heterologous stem-anchor region for an E-protein of a Zika virus; and/or
(c) the nucleic acid molecule encoding an E-protein or a soluble E protein encodes at least one E-protein of a Zika virus or a functional fragment thereof having a mutation L107D in comparison to the sequence of any one of SEQ ID NOs:40 to 52 or 130 to 150; and/or
(d) the nucleic acid molecule encoding an E-protein or a soluble E protein further comprises a sequence encoding a membrane protein of a Zika virus or a functional fragment thereof; and/or
(e) the nucleic acid molecule encoding an E-protein or a soluble E protein does not comprise a nucleic acid sequence encoding a non-structural protein of a flavivirus.

### Claim 19 (depends on 17)

The infectious replicative virus particle according to claim 17, wherein the vector backbone is derived from an attenuated virus measles virus strain selected from the group consisting of the Schwarz strain, the Zagreb strain, the AIK-C strain and the Moraten strain.

### Claim 20 (depends on 17)

The infectious replicative virus particle according to any claim 17, wherein (a) the nucleic acid molecule encoding an E-protein or a soluble E protein comprises a nucleic acid sequence or encodes an amino acid sequence as set forth in any one of SEQ ID NOs: 27 to 39, 53 to 58, 61 to 66, 109 to 129, 151 and 152, or a sequence having at least 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, wherein the nucleic acid molecule encodes at least one functional Zika virus antigen, or (b) the genome of the infectious replicative virus particle comprises a nucleic acid sequence as set forth in SEQ ID NO: 57 or 58 or a sequence having at least 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto wherein the nucleic acid molecule encodes at least one functional Zika virus E-protein antigen or a fragment thereof.

### Claim 21 (depends on 20)

The infections replicative virus particle according to claim 20, wherein the genome of the infectious replicative virus particle comprises a nucleic acid sequence as set forth in SEQ ID NO: 57 or 58.

### Claim 22 (depends on 5, 6, 17)

The infectious replicative virus particle according to claim 17, wherein the nucleic acid molecule encoding an E-protein or a soluble E-protein of a Zika virus comprises a nucleic acid molecule according to claim 5 or 6.

### Claim 23 (depends on 22)

The infectious replicative virus particle according to claim 22, comprising (a) a nucleic acid molecule as set forth in SEQ ID NO: 57 or 58, (b) a nucleic acid molecule as set forth in SEQ ID NO: 60 or 192 comprising a further sequence encoding a sequence of SEQ ID NOs: 27 to 39, 40 to 52, 109 to 129 or 130 to 150 inserted between a BsiWI and a BssHII restriction site of SEQ ID NO:60 or of SEQ ID NO:192, or (c) a sequence having at least 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, wherein the nucleic acid molecule encodes a chimeric recombinant virus particle comprising at least one E-protein of a Zika virus or a functional fragment of an E-protein of a Zika virus.

### Claim 24 (depends on 17)

An immunogenic composition comprising an infectious replicative virus particle according to claim 17 and at least one pharmaceutically and/or veterinarially acceptable carrier and/or excipient.

### Claim 25 (depends on 21)

An immunogenic composition comprising an infectious replicative virus particle according to claim 21 and at least one pharmaceutically and/or veterinarially acceptable carrier and/or excipient.

### Claim 26 (depends on 5)

A host cell comprising a nucleic acid molecule according to claim 5.

### Claim 27 (depends on 17)

A host cell comprising an infectious replicative virus particle according to claim 17.

### Claim 28

A method for producing a recombinant chimeric virus, the method comprising the following steps:
(i) inserting a nucleic acid molecule encoding an E-protein or a soluble E-protein of a Zika virus into a measles virus scaffold vector backbone to operably link the nucleic acid molecule and the vector backbone to obtain a recombinant chimeric virus sequence;
(ii) infecting at least one host cell with at least one recombinant chimeric virus sequence obtained in step (i) to obtain a virus sample;
(iii) clarifying the virus sample of step (ii);
(iv) purifying the clarified virus sample of step (iii);
(v) optionally: formulating the at least one recombinant chimeric virus with at least one pharmaceutically and/or veterinarially acceptable carrier and/or excipient; and
(vi) obtaining a recombinant chimeric virus.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the purification step (iv) comprises purification by means of chromatography, and optionally, wherein purification is followed by an additional polishing step.

### Claim 30 (depends on 28)

The method according to claim 28, wherein the at least one host cell is selected from the group consisting of Vero cells, chicken embryo fibroblast cells, HEK293 cells, HeLa cells, fetal rhesus lung cells or MRC5 cells.

### Claim 31 (depends on 28)

The method according to claim 28, further comprising: (vii) separating recombinant subviral particles from infectious particles.

### Claim 32 (depends on 24)

A method of preventing or treating a Zika virus disease in a subject, comprising administering the immunogenic composition according to claim 24 to the subject.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the immunogenic composition is characterized by a content of contaminating host cell DNA of less than 100 pg/dosis, preferably of less than 75 pg/dosis, more preferably of less than 50 pg/dosis, even more preferably of less than 25 pg/dosis and most preferably of less than 10 pg/dosis, wherein one dosis represents one dosis comprising the immunogenic composition to be administered to a subject in need thereof as a single dose.
